PLA2G7 and diabetic kidney disease: Lp-PLA2 can be used as a biomarker for cardiovascular disease, which can be elevated to two times the normal level when stroke and coronary artery disease occur (Khan and Ilies, 2023), and it can also be used as a potentially specific indicator for the diagnosis of early diabetic nephropathy and for observing the progression of diabetic nephropathy (Zhai et al., 2023).